BMJ is a research journal for Peer-reviewed and research papers.
The median IFR was 0.0003% at 0-19 years, 0.003% at 20-29 years, 0.011% at 30-39 years, 0.035% at 40-49 years, 0.129% at 50-59 years, and 0.501% at 60-69 years.
Evidence based medicine has been corrupted by corporate interests, failed regulation, and commercialisation of academia, argue these authors
Despite the higher positivity rates for Omicron in vaccinated persons, we still found that 91.2% of the Omicron infections in our study occurred in persons who were eligible for 1 or more vaccine doses at the time of PCR testing. In conclusion, escape from vaccine-induced immunity likely contributed to the rapid rise in Omicron infections.
In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines.
Although children and adolescents have a lower burden of SARS-CoV-2-associated disease as compared to adults, assessing absolute risk among children remains difficult due to a high rate of undetected cases. However, without more accurate case numbers, reliable risk analyses are impossible.
Dr. Peter Doshi is a Professor at the University of Maryland and a Senior Editor of the British Medical Journal (BMJ). He recently appeared alongside several other doctors and medical researchers in a panel discussion put on U.S. Sen. Ron Johnson (R-Wis.)
In summary, our results reveal that selection pressure in a highly vaccinated community (>71% fully vaccinated as of early August 2021) favors more infectious, antibody-resistant VOCs such as the gamma12,32 and delta12,13,21,25 variants, and that high-titer symptomatic post-vaccination infections may be a contributor to viral spread.
Background Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear.
The FDA should demand adequate, controlled studies with long term follow up, and make data publicly available, before granting full approval to covid-19 vaccines, says Peter Doshi
But with the US government indicating this week that it plans to start making booster shots widely available next month, experts said the decision not to meet to discuss the data was politically driven.
Eight notable variants of SARS-CoV-2 have been found since September 2020. Elisabeth Mahase reviews the line-up so far
Study Selection SARS-CoV-2 seroprevalence studies with ≥1000 participants aged ≥70 years that presented seroprevalence in elderly people; aimed to generate samples reflecting the general population; and whose location had available data on cumulative COVID-19 deaths in elderly (primary cutoff ≥70 years; ≥65 or ≥60 also eligible).